Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4805246 | 0.98 | HDAC4 (0.64) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| SCHEMBL3443425 | 0.96 | HDAC4 (0.61) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| SCHEMBL3554737 | 0.92 | HSD11B1 (0.58) | HDAC4HSD11B1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1362197 | 0.90 | HDAC4 (0.55) | HDAC4HSD11B1ALDH1A1HDAC1FFAR2 | |
| SCHEMBL503762 | 0.84 | AKR1C1 (0.68) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| SCHEMBL28577323 | 0.82 | HSD11B1 (0.50) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| Hydrochloric Acid SCHEMBL5741878 | 0.82 | AKR1C1 (0.66) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| SCHEMBL28915895 | 0.82 | HDAC4 (0.50) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 | |
| SCHEMBL11282279 | 0.82 | MAPT (0.48) | HDAC4HSD11B1ALDH1A1AKR1C1MAPT | |
| SCHEMBL694700 | 0.82 | AKR1C1 (0.66) | HDAC4HSD11B1ALDH1A1HDAC1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113061098-B | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-113061098-A | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-07-02 | — | — | CN | disclosed |
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8263595-B2 | Triazolopyridine compounds and their use as ask inhibitors | MERCK SERONO SA (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2346865-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2011-07-27 | — | — | EP | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MERCK SERONO SA (CH) | 2010-08-05 | — | — | US | disclosed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | disclosed |
| US-6472394-B1 | MCH antagonists and their use in the treatment of obesity | SCHERING CORPORATION | 2002-10-29 | — | — | US | disclosed |
| US-6464956-B1 | N-METHYL-N-((1-PHENYLCYCLOPENTYL)METHYL) HEPTA(HEXA-, OR PENTA-)METHYLENEIMINIUM CATION TEMPLATE; HYDROCRACKING CATALYST | CHEVRON U.S.A. INC. | 2002-10-15 | — | — | US | disclosed |
| US-6461578-B1 | Using zeolite SSZ-59 for reduction of oxides of nitrogen in a gas stream | CHEVRON U.S.A. INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020085976-A1 | Process for preparing zeolites | CHEVRON U.S.A. INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002051809-A1 | PIPERIDINE MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
| US-4267174-A | AND PROCESS FOR ADMINISTERING | BOEHRINGER MANNHEIM, GMBH (DE) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197681-A1 | Triazolopyridine Compounds and Their Use as Ask Inhibitors | MAP3K5, MAPKAPK5, MAP3K9 | HDAC4 1926/4885HSD11B1 2905/4885ALDH1A1 2574/4885 |
| US-20120238565-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MAP3K5, MAPKAPK5, MAP3K9 | HDAC4 1926/4885HSD11B1 2905/4885ALDH1A1 2574/4885 |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | HDAC4 3076/4885HSD11B1 163/4885ALDH1A1 1134/4885 |
| US-20020169203-A1 | Ion channel modulating agents | KCNN3, KCNN1, KCNN2 | HDAC4 1092/4885HSD11B1 4518/4885ALDH1A1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.